Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Signaling protein signature predicts clinical outcome of non-small-cell lung cancer

Fig. 2

Identification and validation of the 6-protein signature for adeno-carcinoma (ADC). a The ROC curve of the ADC training set. The cutoff point of prognosis scores is shown. b-c Patients of the training set (b) and testing set (c) were classified into poor- and good-prognosis groups using the 6-protein ADC signature. The Kaplan-Meier estimates of overall survival for the two predicted prognosis groups are shown. (d) The prognosis score distribution, prognosis prediction using the ADC signature, the three-year survival status and the expression profile of the 6-protein signature proteins were summarized on ADC patients of BJ cohort. Each column represents an individual patient. e ADC patients of the independent CQ validation cohort were classified into poor- and good-prognosis groups using the 6-protein ADC signature. The Kaplan-Meier survival curves for the two prognosis groups are shown. f The prognosis score distribution, prognosis prediction using the signature, the three-year survival status and the expression profile of the 6-protein signature proteins of CQ ADC patients are shown

Back to article page